Which Medications Are Used to Stop Alcohol Cravings?
An education-only guide to asking about alcohol-craving medication options without dosing, ranking, access, or personal treatment claims.
Three prescription medicines are FDA-approved to treat alcohol use disorder — naltrexone, acamprosate, and disulfiram — and none of them is the single winner. They act on different parts of the problem, suit different goals, and carry different cautions, so the useful question is not which one is strongest but which trade-offs fit your situation. That is a decision to reason through with a clinician. What an article can do is lay the map out fairly.
The short version
- Naltrexone dampens the rewarding lift a drink delivers, so drinking — and wanting to drink — tends to lose some of its pull. It is off the table if you take or depend on opioid pain medication.
- Acamprosate works on the restless, off-balance brain chemistry that can linger after you stop drinking. Its approval is specifically for staying stopped, not for cutting back while still drinking.
- Disulfiram does not touch craving at all. It makes your body react badly to alcohol itself, turning any drink into a fast, unpleasant experience — deterrence, chosen on purpose.
- None of the three treats withdrawal, and none is meant to work alone; the labels and guidelines all pair medication with counseling or other support.
Each option below gets the same three questions, in the same order, because the fairest way to compare them is to notice how differently they act. A peer-reviewed comparison of the three makes the contrast plain: one blocks reward, one helps restore chemical balance, one makes drinking physically punishing.
Naltrexone
What it is. A tablet that is FDA-indicated for the treatment of alcohol dependence — the formal name for drinking that keeps overriding your own decisions about it.
How it is thought to work. Alcohol triggers a release of the brain's own feel-good chemicals, which land on the same receptors that opioid drugs use. The American Academy of Family Physicians' review of these medicines explains that those receptors likely carry much of drinking's pleasant effect, and that naltrexone works by blocking them. The practical result, as SAMHSA describes it, is that cravings ease and the amount people drink tends to fall.
The key caution. Because it blocks opioid receptors, the label rules it out for anyone taking opioid painkillers, dependent on opioids, or in opioid withdrawal — it would cancel the pain relief and can set off withdrawal. The same label is also plain that the tablet has not been shown to help except as part of a broader plan for the drinking itself.
Acamprosate
What it is. A medicine FDA-approved for maintenance of abstinence — plain English: helping someone who has already stopped drinking stay stopped. It is the only one of the three whose approval is built entirely around that after-you-quit stretch.
How it is thought to work. Months or years of heavy drinking push the brain to re-tune its main excitatory "go" signaling to compensate for alcohol's constant dampening. Stop drinking and that re-tuning is still there, which is part of why early sobriety can feel wired, restless, and raw. In the pharmacology literature, acamprosate is described as helping that over-revved system settle back toward its normal balance.
The key caution. It is not a medicine for someone still drinking daily, and not a withdrawal treatment — the approval assumes you have already stopped. One practical detail from the same safety literature: it leaves the body through the kidneys rather than the liver, so kidney health is what a clinician checks first — and that liver-sparing route is also why it often comes up for people whose liver is already strained.
Disulfiram
What it is. The oldest of the three. Its FDA label describes it as an aid for people who want to remain in a state of enforced sobriety — and says outright that it is not a cure.
How it is thought to work. Your body breaks alcohol down in two steps, and disulfiram blocks the second step, so a toxic in-between product called acetaldehyde piles up if you drink. The reaction — flushing, nausea, a pounding heart — arrives fast. Disulfiram does not quiet the desire for a drink; it raises the immediate cost of acting on one, which is a genuinely different job.
The key caution. The whole design depends on wanting the tripwire. Someone ambivalent can simply stop taking it, and drinking on it is not a mild experience — the reaction is the mechanism, not a side effect.
Side by side
| Naltrexone | Acamprosate | Disulfiram | |
|---|---|---|---|
| Acts on | the reward a drink delivers | the lingering "go"-signal imbalance after quitting | how the body breaks alcohol down |
| FDA-approved for | treatment of alcohol dependence | staying stopped after quitting | enforced sobriety for people committed to abstinence |
| If you drink on it | the drink lands flatter; no built-in sickness | no built-in reaction | flushing, nausea, pounding heart |
| First thing a clinician checks | any opioid use | whether you have already stopped; kidney health | whether you actually want the deterrent |
Where the evidence is stronger — and where it is honestly thin
AHRQ's systematic review of AUD medication in outpatient care found moderate-strength evidence that oral naltrexone and acamprosate each reduce return to drinking, while judging the evidence for disulfiram against placebo inadequate. Inadequate evidence is not proof a medicine fails — but it does mean the first two carry more research weight. The AAFP's guidance lands in a similar place: it groups acamprosate and naltrexone as the better-supported approved options, keeps disulfiram as an alternative, and recommends pairing any of them with behavioral support rather than relying on a tablet alone.
That guidance also answers the obvious follow-up — are these three really the whole list? For FDA-approved options, yes. Beyond them, AAFP notes that some clinicians prescribe topiramate, a seizure medicine, off-label for alcohol use disorder. Off-label is not a shortcut around the clinician conversation; it moves the decision deeper into individual-judgment territory, not out of it.
Match the medicine to the goal, not the other way around
The clearest practical difference among the three is where each one meets you. Trying to cut back rather than quit entirely? Acamprosate's approval assumes you have stopped, and disulfiram makes any drinking miserable — so that goal points the conversation toward naltrexone's reward-dampening lane, and toward an honest look at whether cutting back is realistic for your pattern. Already stopped and fighting to stay there? That after-quit stretch is exactly what acamprosate was approved for, and it is also where disulfiram's tripwire logic appeals to some people. Still drinking heavily every day? Then the first question is not craving medication at all but how to stop safely — alcohol withdrawal has its own risks and its own plan, and if stopping has ever brought on severe shaking, confusion, hallucinations, or a seizure, that is a call-911 moment, not a medication-comparison moment.
Most people never get this conversation
In 2024, an estimated 27.9 million Americans ages 12 and older had past-year alcohol use disorder — about 9.7% of that age group — yet roughly 2.1 million of them, about 7.6%, received any alcohol treatment that year, and AAFP observes that most people with the disorder are never offered medication at all.
That gap says nothing about whether the medicines work. It is an access and awareness problem: the conversation simply never happens.
Questions worth bringing to a clinician
- Given my goal — cutting back versus stopping — which of these am I even eligible for?
- What in my health history (opioid prescriptions, kidney or liver concerns, pregnancy, other medications) rules any of them out?
- What support goes alongside the medicine, since none of these is meant to work alone?
- If the first one we try is a poor fit, what is the next move?
For most people the hard step is not choosing among three medicines — it is getting the conversation to happen at all. If you do not have a clinician to bring these questions to, that is the specific gap Clero is built to close: it connects you with a licensed clinician by telehealth who can go through your history and weigh whether a craving medication such as naltrexone fits your situation.
No winner, on purpose
Naltrexone dampens the reward. Acamprosate steadies the after-quit imbalance. Disulfiram raises the price of a slip. Three different jobs — and which job needs doing is a fact about you, your goal, and your health, not a fact about the medicines. That is why the honest close here is not a pick but a fit question, and fit is what the clinician conversation is for. For a deeper look at any single option, see the explainers on naltrexone, acamprosate, and disulfiram.
This is general education, not medical advice or a prescribing guide. If stopping drinking has ever caused severe shaking, confusion, or a seizure, treat it as an emergency and call 911. If you are having thoughts of harming yourself, call or text 988. For confidential treatment referrals, SAMHSA's National Helpline is 1-800-662-HELP (4357).
Want the private naltrexone update?
Join the launch list to hear first. Today, this is still educational content, not a prescription request or clinical intake.